Jason M Uslaner

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Subthalamic nucleus lesions increase impulsive action and decrease impulsive choice - mediation by enhanced incentive motivation?
    Jason M Uslaner
    Biopsychology and Neuroscience Programs, Department of Psychology, University of Michigan, East Hall, 525 E University Street, Ann Arbor, MI 48019 1109, USA
    Eur J Neurosci 24:2345-54. 2006
  2. ncbi request reprint T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats
    Jason M Uslaner
    Department of Neuroscience, Merck and Co, Inc, WP46 300, 770 Sumneytown Pike, PO Box 4, West Point, PA 19486, USA
    Neuropharmacology 62:1413-21. 2012
  3. pmc The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
    Anthony L Gotter
    Department of Neuroscience, Merck Research Laboratories, West Point, PA, USA
    BMC Neurosci 14:90. 2013
  4. ncbi request reprint Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement
    Jason M Uslaner
    Departments of Pharmacology, Merck and Co, Inc, West Point, PA 19486, USA Electronic address
    Behav Brain Res 269:61-5. 2014
  5. ncbi request reprint Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition
    Jason M Uslaner
    Merck and Co Inc, WP46 100, 770 Sumneytown Pike, P O Box 4, West Point, PA 19486, USA
    Sci Transl Med 5:179ra44. 2013
  6. ncbi request reprint The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque
    Jason M Uslaner
    Merck Research Laboratories, Merck and Co, Inc, West Point, PA 19486, USA
    Psychopharmacology (Berl) 225:21-30. 2013
  7. ncbi request reprint T-type calcium channel antagonism decreases motivation for nicotine and blocks nicotine- and cue-induced reinstatement for a response previously reinforced with nicotine
    Jason M Uslaner
    Department of Neuroscience, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Biol Psychiatry 68:712-8. 2010
  8. ncbi request reprint Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose
    Jason M Uslaner
    Department of Schizophrenia Research, Merck and Co, Inc, Ann Arbor, MI 48019 1109, USA
    Behav Brain Res 207:37-43. 2010
  9. ncbi request reprint Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants
    Jason M Uslaner
    Department of Schizophrenia Research, Merck and Co, Inc, 770 Sumneytown Pike, West Point, PA 19486, USA
    Psychopharmacology (Berl) 206:641-51. 2009
  10. ncbi request reprint Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus
    Jason M Uslaner
    Department of Schizophrenia Research, Merck and Co, Inc, West Point, PA 19486, USA
    Neuropharmacology 57:531-8. 2009

Detail Information

Publications29

  1. ncbi request reprint Subthalamic nucleus lesions increase impulsive action and decrease impulsive choice - mediation by enhanced incentive motivation?
    Jason M Uslaner
    Biopsychology and Neuroscience Programs, Department of Psychology, University of Michigan, East Hall, 525 E University Street, Ann Arbor, MI 48019 1109, USA
    Eur J Neurosci 24:2345-54. 2006
    ..These findings suggest that the STN may serve as a novel target for the treatment of psychological disorders characterized by deficits in behavioral control, such as drug addiction and attention deficit hyperactivity disorder...
  2. ncbi request reprint T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats
    Jason M Uslaner
    Department of Neuroscience, Merck and Co, Inc, WP46 300, 770 Sumneytown Pike, PO Box 4, West Point, PA 19486, USA
    Neuropharmacology 62:1413-21. 2012
    ..Basal, amphetamine- and MK-801-induced dopamine efflux was altered. These findings suggest that T-type calcium channel antagonism could represent a novel mechanism for treating schizophrenia...
  3. pmc The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
    Anthony L Gotter
    Department of Neuroscience, Merck Research Laboratories, West Point, PA, USA
    BMC Neurosci 14:90. 2013
    ..These features of an ideal compound are not only dependent upon pharmacokinetics, receptor binding kinetics, potency and pharmacodynamic activity, but also upon a compound's mechanism of action...
  4. ncbi request reprint Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement
    Jason M Uslaner
    Departments of Pharmacology, Merck and Co, Inc, West Point, PA 19486, USA Electronic address
    Behav Brain Res 269:61-5. 2014
    ..These findings indicate that orexin 2 receptor antagonism might have utility for attenuating relapse, particularly for patients sensitive to environmental stimuli associated with drug taking...
  5. ncbi request reprint Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition
    Jason M Uslaner
    Merck and Co Inc, WP46 100, 770 Sumneytown Pike, P O Box 4, West Point, PA 19486, USA
    Sci Transl Med 5:179ra44. 2013
    ..These findings suggest that DORAs might provide an effective treatment for insomnia with a greater therapeutic margin for sleep versus cognitive disturbances compared to the GABAA-positive allosteric modulators currently in use...
  6. ncbi request reprint The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque
    Jason M Uslaner
    Merck Research Laboratories, Merck and Co, Inc, West Point, PA 19486, USA
    Psychopharmacology (Berl) 225:21-30. 2013
    ....
  7. ncbi request reprint T-type calcium channel antagonism decreases motivation for nicotine and blocks nicotine- and cue-induced reinstatement for a response previously reinforced with nicotine
    Jason M Uslaner
    Department of Neuroscience, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Biol Psychiatry 68:712-8. 2010
    ..Recent evidence suggests an involvement of T-type calcium channels in the effects of drugs of abuse...
  8. ncbi request reprint Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose
    Jason M Uslaner
    Department of Schizophrenia Research, Merck and Co, Inc, Ann Arbor, MI 48019 1109, USA
    Behav Brain Res 207:37-43. 2010
    ..Here we examined the effects of a glycine transporter (GlyT1) inhibitor, which elevates glycine and hence NMDA signaling, on the behavioral effects of nicotine...
  9. ncbi request reprint Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants
    Jason M Uslaner
    Department of Schizophrenia Research, Merck and Co, Inc, 770 Sumneytown Pike, West Point, PA 19486, USA
    Psychopharmacology (Berl) 206:641-51. 2009
    ..However, at the single, potentially suboptimal, dose that was tested, LY2140023 trended towards being inferior to olanzapine on several indices of efficacy within the Positive and Negative Syndrome Scale...
  10. ncbi request reprint Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus
    Jason M Uslaner
    Department of Schizophrenia Research, Merck and Co, Inc, West Point, PA 19486, USA
    Neuropharmacology 57:531-8. 2009
    ..These findings may have important implications for the development of mGluR5 PAMs to treat schizophrenia...
  11. ncbi request reprint The influence of subthalamic nucleus lesions on sign-tracking to stimuli paired with food and drug rewards: facilitation of incentive salience attribution?
    Jason M Uslaner
    Department of Schizophrenia, Merck Research Laboratories, West Point, PA 19486, USA
    Neuropsychopharmacology 33:2352-61. 2008
    ..Activity in this neural system may help mitigate the development of compulsive behavioral disorders, such as addiction, which are characterized by pathological control over behavior by reward-associated cues...
  12. ncbi request reprint The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey
    Sean M Smith
    Neuroscience, Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA 19486, USA
    Neuropharmacology 64:215-23. 2013
    ..This article is part of a Special Issue entitled 'Cognitive Enhancers'...
  13. ncbi request reprint The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys
    Christopher E Cannon
    Merck Research Laboratories 44E 200, 770 Sumneytown Pike, West Point, PA 19486, USA
    Neuropharmacology 64:191-6. 2013
    ..This article is part of a Special Issue entitled 'Cognitive Enhancers'...
  14. ncbi request reprint Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure
    Christopher J Winrow
    Depression and Circadian Disorders Department, Merck Research Laboratories, West Point, PA, USA
    Neuropharmacology 58:185-94. 2010
    ....
  15. ncbi request reprint MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?
    Joshua D Vardigan
    Merck and Co, Inc, West Point, PA 19486, USA
    Pharmacol Biochem Behav 95:223-9. 2010
    ..These data suggest that this model may be useful for identifying novel agents that improve negative symptoms, and that compounds which enhance NMDA receptor function, such as mGlu5 receptor PAMs, may have clinical utility in this regard...
  16. ncbi request reprint Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration
    Sophie Parmentier-Batteur
    Department of Psychiatry, Merck and Co, Inc, West Point, PA 19486, USA
    Neuropharmacology 62:1453-60. 2012
    ....
  17. pmc Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats
    Steven V Fox
    Department of Neuroscience, Merck Research Laboratories, Merck Corporation, West Point, PA, USA
    Neuropsychopharmacology 38:2401-8. 2013
    ..These results suggest that DORA-22 differs from eszopiclone and zolpidem whereby DORA-22 promotes somnolence without altering the neuronal network EEG activity observed during normal sleep. ..
  18. ncbi request reprint The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine
    Sean M Smith
    Department of Schizophrenia Research, Merck and Co, Inc, WP46 100, 770 Sumneytown Pike, P O Box 4, West Point, PA 19486, USA
    J Pharmacol Exp Ther 328:921-30. 2009
    ....
  19. ncbi request reprint Cocaine-induced psychomotor activity is associated with its ability to induce c-fos mRNA expression in the subthalamic nucleus: effects of dose and repeated treatment
    Jason M Uslaner
    Biopsychology Program, Department of Psychology, The University of Michigan, East Hall, 525 E University St, Ann Arbor, MI 48019 1109, USA
    Eur J Neurosci 17:2180-6. 2003
    ..These findings may have implications concerning the neurobiological mechanisms underlying the behavioural effects of psychostimulant drugs...
  20. ncbi request reprint Subthalamic nucleus lesions enhance the psychomotor-activating, incentive motivational, and neurobiological effects of cocaine
    Jason M Uslaner
    Department of Psychology, University of Michigan, Ann Arbor, Michigan 48019 1109, USA
    J Neurosci 25:8407-15. 2005
    ..Thus, the STN may serve as a novel target for therapeutic interventions aimed at treating drug dependence...
  21. ncbi request reprint The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling
    Stefania Risso Bradley
    MRL Department of Neuroscience, Merck and Co, Inc, West Point, PA, USA
    Pharmacol Biochem Behav 101:35-40. 2012
    ..Therefore, our findings confirm the hypothesis that mGluR7 could represent a novel target for treating depression...
  22. ncbi request reprint Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators
    Anthony L Gotter
    Department of Neuroscience, Merck Research Laboratories, 770 Sumneytown Pike, PO Box 4, West Point, PA 19486 0004, USA
    BMC Neurosci 15:109. 2014
    ..The current study compares the role and interdependence of these two mechanisms on their ability to influence sleep architecture and quantitative electroencephalography (qEEG) spectral profiles across preclinical species...
  23. ncbi request reprint The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task
    Joshua D Vardigan
    In Vivo Pharmacology, Merck and Co, Inc, West Point, PA 19486, USA
    J Neurogenet 25:120-6. 2011
    ..These data confirm and extend the hypothesis that PDE9 inhibition might serve as a novel treatment for AD and age-related cognitive decline...
  24. ncbi request reprint 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts
    Edward J Brnardic
    Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA
    Bioorg Med Chem Lett 20:3129-33. 2010
    ..An optimized lead compound was found to be brain penetrant and active in a rat ketamine-induced hyperlocomotion model for antipsychotic activity...
  25. ncbi request reprint The attribution of incentive salience to a stimulus that signals an intravenous injection of cocaine
    Jason M Uslaner
    Biopsychology and Neuroscience Programs, Department of Psychology, The University of Michigan, Ann Arbor, MI 48019 1109, USA
    Behav Brain Res 169:320-4. 2006
    ..Delineating the neurobiological mechanisms responsible for this process will be important for understanding and treating drug addiction...
  26. ncbi request reprint Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target
    Sophie Parmentier-Batteur
    Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA 19486 0004, USA Electronic address
    Neuropharmacology 82:161-73. 2014
    ..This study reveals for the first time that augmentation of mGlu5 function with selective allosteric modulators results in neurotoxicity...
  27. ncbi request reprint Methamphetamine-induced structural plasticity in the dorsal striatum
    Jakub P Jedynak
    Neuroscience Program, The University of Michigan, Ann Arbor, MI, USA
    Eur J Neurosci 25:847-53. 2007
    ....
  28. pmc The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors
    Sean M Smith
    Merck and Co, Inc, West Point, PA, USA
    Open Med Chem J 4:3-9. 2010
    ..This article highlights and reviews research advances for DAAO inhibitors published in peer reviewed journals...
  29. ncbi request reprint Amphetamine-induced c-fos mRNA expression in the caudate-putamen and subthalamic nucleus: interactions between dose, environment, and neuronal phenotype
    Jason M Uslaner
    Biopsychology and Neuroscience Programs, Department of Psychology, The University of Michigan, Ann Arbor, Michigan 48019, USA
    J Neurochem 85:105-14. 2003
    ....